The in vivo gene therapy industry focuses on developing treatments that directly modify a patient’s genome to correct genetic disorders. This segment includes companies using technologies like viral vectors to deliver therapeutic genes into cells. They often target diseases ranging from rare genetic conditions to common ailments and leverage advances in biotechnology to improve patient outcomes. As regulatory pathways evolve and clinical trials yield promising results, the market is poised for substantial growth, attracting increased interest from investors who recognize its potential to revolutionize healthcare.

The companies listed here vary in size and specialization, with headquarter locations spread across the United States, China, and Europe. Some, like Spark Therapeutics, have substantial teams exceeding 500 employees, while others, such as Regel Therapeutics, are smaller startups with fewer than 50 staff. Founded between the late 1990s and the late 2010s, these companies aim to tackle significant unmet medical needs in areas such as ophthalmic, neurological, and chronic diseases through innovative gene therapy approaches.

Read on to discover the top in vivo gene therapy companies.

Top 23 In Vivo Gene Therapy Companies

1. Spark Therapeutics, Inc.

• Website: sparktx.com
• Ownership type: Corporate
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $4.3B, February 2019
• Founded year: 2013
• Headcount: 501-1000
• LinkedIn: spark-therapeutics-inc

Spark Therapeutics, Inc., based in Philadelphia, Pennsylvania, is a biotechnology company that specializes in gene therapy aimed at treating genetic diseases. Founded in 2013, Spark has developed a strong focus on conditions such as hemophilia and inherited retinal diseases. The company is known for its innovative approach to gene therapy, utilizing a proprietary adeno-associated viral (AAV) platform to create therapies that can potentially provide long-lasting effects for patients. Spark's commitment to transforming patient care is evident in their research, development, and manufacturing processes. They have made significant strides in the industry, including the launch of Luxturna, the first approved gene therapy for a genetic disease in both the U.S. and EU. In 2019, Spark Therapeutics secured substantial funding, amounting to $4.3 billion, which underscores investor confidence in their mission and capabilities. The company is also a member of the Roche Group, further enhancing its position in the biotechnology landscape.

2. Agtc

• Website: agtc.com
• Ownership type: Venture Capital
• Headquarters: Alachua, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $23.5M, October 2022
• Founded year: 1999
• Headcount: 51-200
• LinkedIn: agtc

Agtc, now known as Beacon Therapeutics, is a biotechnology firm based in Alachua, Florida, specializing in gene therapy aimed at treating retinal diseases. Founded in 1999, the company has carved out a niche in the ophthalmic sector, focusing on conditions such as X-Linked Retinitis Pigmentosa, Dry Age-related Macular Degeneration, and Cone Rod Dystrophy. Their flagship product, AGTC-501, is an AAV vector-based gene therapy currently undergoing Phase 2/3 clinical trials, showcasing their commitment to addressing significant unmet medical needs in vision restoration. The company has also received $23.5 million in funding as of October 2022, which supports their ongoing clinical research and development initiatives. Beacon Therapeutics aims to transform the treatment landscape for patients suffering from blinding retinal diseases, emphasizing innovative approaches to gene therapy.

3. AskBio Inc.

• Website: askbio.com
• Ownership type: Corporate
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 75%, United Kingdom (UK) 14%, France 6%, Other 5%
• Latest funding: $2.0B, October 2020
• Founded year: 2001
• Headcount: 501-1000
• LinkedIn: askbio

AskBio Inc., formally known as Asklepios BioPharmaceutical, Inc., is a biotechnology company based in Durham, North Carolina. Founded in 2001, AskBio is dedicated to developing innovative gene therapies aimed at treating genetic diseases. The company leverages its advanced AAV gene therapy technology to create life-saving treatments. AskBio collaborates with researchers and healthcare providers to address significant unmet medical needs across a range of genetic conditions. With a workforce of approximately 508 employees, the company has established a strong presence in the gene therapy space. Notably, AskBio has received substantial funding, including a remarkable $2 billion in 2020, which supports its ongoing research and development efforts. Their clinical pipeline includes programs targeting neuromuscular conditions, central nervous system disorders, cardiovascular diseases, and ultra-rare genetic conditions, showcasing their commitment to advancing genetic medicine.

4. EdiGene Inc.

• Website: edigene.com
• Ownership type: Private Equity
• Headquarters: Beijing, Beijing, China
• Employee distribution: China 100%
• Latest funding: Series B, $61.6M, April 2021
• Founded year: 2015
• Headcount: 201-500
• LinkedIn: edigene

EdiGene Inc., founded in 2015 and based in Beijing, China, is a biotechnology firm dedicated to pioneering gene editing and therapy solutions. The company focuses on addressing significant unmet medical needs, particularly in cancer and genetic disorders, through its advanced platforms. EdiGene's LEAPER technology enables precise RNA editing, while the MAGIC platform is designed for cell therapy applications. The company has been involved in various clinical trials, including those targeting Duchenne Muscular Dystrophy and other genetic conditions. EdiGene has also secured substantial funding, with a Series B round raising over $61 million in 2021, which underscores its growth potential and commitment to innovation in the gene therapy sector.

5. Regel Therapeutics

• Website: regeltherapeutics.com
• Ownership type: Private
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $1.0M, September 2023
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: regel-therapeutics

Regel Therapeutics is a private biotechnology firm based in Boston, Massachusetts, founded in 2020. The company specializes in targeted gene therapy aimed at treating severe genetic diseases. Utilizing their proprietary T3 platform, Regel Therapeutics focuses on correcting abnormal gene expression through a unique approach that combines AAV delivery with a programmable dCas system. This technology allows for precise modulation of gene expression in disease-affected cells, which is crucial for addressing conditions that currently lack effective treatments. Their pipeline includes programs targeting Dravet syndrome and SCN2A haploinsufficiency, both of which are serious genetic disorders. In September 2023, Regel Therapeutics secured $1 million in funding, indicating ongoing support for their innovative research and development efforts in the biotechnology sector.

6. AAVantgarde Bio

• Website: aavantgarde.com
• Ownership type: Venture Capital
• Headquarters: Milan, Lombardy, Italy
• Employee distribution: United Kingdom (UK) 49%, Italy 44%, Switzerland 7%
• Latest funding: Series A, $65.3M, June 2023
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: aavantgarde-bio

AAVantgarde Bio is a clinical-stage biotechnology company based in Milan, Italy, founded in 2021. The company specializes in gene therapy, focusing on developing innovative treatments for inherited retinal diseases. AAVantgarde operates proprietary AAV vector platforms that address the limitations of traditional gene delivery methods, particularly the small DNA cargo capacity of AAV vectors. Their technology enables the delivery of larger genes, which opens new avenues for treating genetic disorders. The company has a clear mission to broaden the application of AAV-based therapies for underserved patients. AAVantgarde has received significant funding, including a €61 million Series A financing round in June 2023, which will help advance their clinical programs. Their current pipeline includes two lead programs targeting Usher syndrome type 1B and Stargardt disease, both of which are in clinical trials. AAVantgarde's commitment to addressing high unmet needs in genetic medicine positions them as a relevant player in the in vivo gene therapy sector.

7. iECURE, inc.

• Website: iecure.com
• Ownership type: Venture Capital
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $65.0M, November 2022
• Founded year: 2012
• Headcount: 11-50
• LinkedIn: iecure

iECURE, inc. is a biotechnology firm based in Philadelphia, Pennsylvania, founded in 2012. The company is dedicated to developing innovative therapeutics for genetic disorders, with a particular emphasis on liver diseases. iECURE employs advanced gene editing techniques, specifically focusing on in vivo gene insertion methods. Their primary target is to address 'loss of function' liver disorders, which affect thousands of patients, especially children, each year. The company collaborates closely with the University of Pennsylvania's Gene Therapy Program, leveraging their expertise in vector engineering and gene therapy development. Recently, iECURE secured $65 million in Series A funding, which underscores the confidence investors have in their mission to create effective treatments for rare genetic conditions. Their current pipeline includes therapies for ornithine transcarbamylase deficiency and other urea cycle disorders, showcasing their commitment to tackling significant unmet medical needs.

8. SalioGen Therapeutics

• Website: saliogen.com
• Ownership type: Venture Capital
• Headquarters: Lexington, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $115.0M, January 2022
• Founded year: 2020
• Headcount: 51-200
• LinkedIn: saliogen

SalioGen Therapeutics, founded in 2020 and based in Lexington, Massachusetts, is a biotechnology firm dedicated to advancing genetic medicine. The company specializes in innovative therapies utilizing its proprietary Gene Coding technology, which enables the integration of large DNA sequences into the genome at specific locations. This method avoids the complications associated with viral vectors and double-stranded breaks, making it a promising approach for treating genetic disorders. SalioGen's pipeline includes therapies aimed at cystic fibrosis and Stargardt disease, among other genetic conditions. The company has attracted significant venture capital funding, with a Series B round raising $115 million in early 2022, underscoring its potential in the genetic medicine space. SalioGen's commitment to developing effective treatments positions it as a noteworthy player in the in vivo gene therapy industry.

9. Prevail Therapeutics

• Website: prevailtherapeutics.com
• Ownership type: Corporate
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $880.0M, December 2020
• Founded year: 2017
• Headcount: 51-200
• LinkedIn: prevail-therapeutics

Prevail Therapeutics, founded in 2017 and based in New York City, is a biotechnology firm dedicated to developing innovative gene therapies for neurodegenerative diseases. The company targets conditions such as Parkinson's disease, Gaucher disease, and frontotemporal dementia, aiming to create disease-modifying treatments that address the underlying genetic causes of these disorders. Prevail employs a precision medicine approach, focusing on genetically defined patient populations with urgent unmet needs. Their pipeline includes several AAV9-based gene therapy candidates, currently in various stages of clinical trials. Notably, Prevail has received significant funding, totaling $880 million, which underscores investor confidence in their mission and potential impact in the field. In 2021, Prevail was acquired by Eli Lilly and Company, further solidifying its position within the biotechnology landscape.

10. Ensoma

• Website: ensoma.com
• Ownership type: Private Equity
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 97%, Denmark 3%
• Latest funding: Series B, $50.0M, May 2023
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: ensomabio

Ensoma is a biotechnology firm based in Boston, Massachusetts, founded in 2019. The company specializes in creating innovative medical treatments through its proprietary Engenious™ platform. This platform is designed to develop one-time in vivo therapies that can precisely engineer immune cells to address various diseases, including cancer, autoimmune disorders, and inherited conditions. Ensoma's approach is notable for its combination of advanced delivery technology and a comprehensive DNA editing toolkit, enabling the creation of smarter, more effective therapeutic solutions. The company has attracted significant investment, securing $85 million in funding to enhance its portfolio of in vivo engineered cellular medicines. Ensoma's commitment to pioneering new medical approaches positions it as a noteworthy entity in the biotechnology sector.

11. FinVector Oy

• Website: finvector.com
• Ownership type: Private
• Headquarters: Kuopio, North Savo, Finland
• Employee distribution: Finland 99%
• Latest funding: Other (Debt), $48.2M, June 2023
• Founded year: 1993
• Headcount: 201-500
• LinkedIn: finvector-vision-therapies-oy

FinVector Oy, based in Kuopio, Finland, is a biopharmaceutical company that specializes in the manufacturing of viral-based gene therapy products. Founded in 1993, the company has built a reputation for its commitment to improving the lives of patients with chronic health conditions, particularly those suffering from bladder cancer. FinVector operates a state-of-the-art cGMP manufacturing facility, which adheres to the highest standards of safety and efficacy in the production of gene therapy products. Recently, the company opened a new global manufacturing hub, Finport, which focuses on producing the viral vector-based drug substance for Ferring Pharmaceuticals’ FDA-approved gene therapy, Adstiladrin. This facility not only enhances their manufacturing capabilities but also positions FinVector as a significant player in the gene therapy market. The company has received substantial funding, with a recent amount of approximately €48 million reported in June 2023, indicating ongoing investment in their operations and growth.

12. Carbon Biosciences

• Website: carbonbio.com
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $38.0M, June 2022
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: c12bio

Carbon Biosciences, founded in 2021 and based in Boston, Massachusetts, is a biotechnology firm dedicated to advancing gene therapy and genetic medicines. The company aims to develop innovative treatments for genetic diseases by harnessing the power of natural viral evolution. Their proprietary CBN vector library is designed to offer advantages such as enhanced tissue specificity and the ability to deliver larger payloads, which are crucial for effective gene therapy. Carbon Biosciences has attracted significant investment, securing $38 million in a Series A funding round in June 2022. This funding supports their mission to create advanced therapeutic solutions for healthcare providers and pharmaceutical companies, particularly in the area of cystic fibrosis. With a team of passionate drug developers, Carbon is committed to pushing the boundaries of genetic medicine and delivering on the promise of effective treatments.

13. Jaguar Gene Therapy

• Website: jaguargenetherapy.com
• Ownership type: Venture Capital
• Headquarters: Lake Forest, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: March 2022
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: jaguargenetherapy

Jaguar Gene Therapy, founded in 2019 and based in Lake Forest, Illinois, is a biotechnology firm dedicated to creating innovative gene therapies for severe genetic diseases. The company leverages advanced manufacturing techniques and adeno-associated virus (AAV)-based delivery systems to develop safe and effective treatments. Their mission is to address the critical needs of patients and families affected by genetic disorders, aiming to improve health outcomes through targeted therapies. Jaguar Gene Therapy is currently advancing a pipeline that includes therapies for conditions such as galactosemia and severe neurodevelopmental disorders linked to the SHANK3 gene. The company emphasizes product purity and patient safety, partnering with Advanced Medicine Partners to ensure high-quality manufacturing processes. With a team of experts experienced in gene therapy development, Jaguar is positioned to make significant contributions to the field.

14. HuidaGene Therapeutics

• Website: huidagene.com
• Ownership type: Venture Capital
• Headquarters: Shanghai, Shanghai, China
• Employee distribution: China 88%, United States (USA) 12%
• Latest funding: Series C, May 2022
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: %e8%be%89%e5%a4%a7%ef%bc%88%e4%b8%8a%e6%b5%b7%ef%bc%89%e7%94%9f%e7%89%a9%e7%a7%91%e6%8a%80%e6%9c%89%e9%99%90%e5%85%ac%e5%8f%b8

HuidaGene Therapeutics, founded in 2018 and based in Shanghai, China, is a biotechnology firm focused on gene editing and gene therapies. The company aims to transform genomic medicine by developing innovative treatments for genetic disorders, with a particular emphasis on neurology and ophthalmology. HuidaGene has established a robust pipeline targeting conditions such as MECP2 Duplication Syndrome, Huntington's Disease, and various inherited retinal dystrophies. Their proprietary technology platforms, including the HG-AAV platform, support their research and development efforts. The company has also made notable progress in clinical trials, having received IND clearance for their gene therapy products from regulatory bodies like the FDA. With a dedicated team and a clear mission to address global patient needs, HuidaGene is positioned as a significant player in the gene therapy industry.

15. Arbor Biotechnologies

• Website: arbor.bio
• Ownership type: Private Equity
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series C, $73.9M, March 2025
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: arborbio

Arbor Biotechnologies, founded in 2016 and based in Cambridge, Massachusetts, is a biotechnology company dedicated to advancing genetic medicines through innovative gene editing technologies. The firm specializes in creating programmable DNA editors aimed at addressing genetic diseases. Their approach is centered on the belief that genetic disease treatment should be personalized, utilizing a unique toolbox of next-generation gene editors that can target over 93% of the human genome. Arbor's pipeline focuses on critical areas such as liver and CNS diseases, reflecting their commitment to tackling significant health challenges. The company has attracted substantial investment, including a recent Series C funding round of $73.9 million, which underscores their active role in the biotechnology sector and their potential to deliver impactful genetic therapies. Arbor's leadership team comprises experienced professionals from various backgrounds, enhancing their capability to innovate and execute in the competitive landscape of gene therapy.

16. AnLong Bio

• Website: anlongbio.com
• Ownership type: Venture Capital
• Headquarters: Beijing, Beijing, China
• Employee distribution: China 100%
• Latest funding: Series A, January 2024
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: anlongbio

AnLong Bio, founded in 2019 and based in Beijing, China, is a biotechnology firm focused on gene therapy for rare diseases. The company aims to develop and commercialize innovative treatments that address significant clinical needs. AnLong Bio has built a robust network of clinical and manufacturing experts, which enhances its capability to deliver effective therapies. They have established platforms for adeno-associated virus (AAV) and RNA interference (RNAi), which are essential for their therapeutic development. In 2023, AnLong Bio received approval for a clinical trial of their AAV gene therapy product, AL-001, targeting age-related macular degeneration. This reflects their commitment to advancing gene therapy solutions. The company has also secured funding through a Series A round, which supports its growth and development initiatives.

17. Amarna Therapeutics

• Website: amarnatherapeutics.com
• Ownership type: Venture Capital
• Headquarters: Leiden, South Holland, Netherlands
• Employee distribution: Netherlands 88%, Spain 12%
• Latest funding: Other (Grant), January 2022
• Founded year: 2008
• Headcount: 11-50
• LinkedIn: amarna-therapeutics-b.v.

Amarna Therapeutics is a biotechnology firm based in Leiden, Netherlands, founded in 2008. The company specializes in gene therapy, aiming to develop innovative treatments for a range of diseases, including Type 1 Diabetes and Hemophilia. Utilizing its proprietary Nimvec™ platform, Amarna Therapeutics focuses on delivering transformative therapies that have the potential to be curative. Their pipeline also includes targets for obesity, multiple sclerosis, and age-related macular degeneration. The company is actively engaged in the industry, as demonstrated by their recent constructive feedback from the FDA regarding their AM510 gene therapy development. With a small team of around 17 employees, Amarna Therapeutics is backed by venture capital and continues to pursue advancements in gene therapy.

18. Aro Biotherapeutics

• Website: arobiotx.com
• Ownership type: Venture Capital
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 96%, Bangladesh 4%
• Latest funding: Series B, $41.5M, November 2023
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: aro-biotherapeutics

Aro Biotherapeutics, founded in 2018 and based in Philadelphia, Pennsylvania, is a biotechnology company dedicated to the development of targeted genetic medicines. Utilizing their proprietary Centyrin platform, Aro is pioneering the creation of therapeutic candidates that aim to address complex diseases through precise modulation of gene targets in affected tissues. The company is actively engaged in developing a pipeline of Centyrin-based therapeutic candidates, including Centyrin-siRNA conjugates, which are designed to enhance the delivery of oligonucleotide-based therapies. Aro's focus on tissue-specific targeting is particularly relevant in the context of in vivo gene therapy, as it seeks to improve the efficacy and safety of treatments. In November 2023, Aro secured $41.5 million in Series B funding, underscoring investor confidence in their innovative approach and potential impact in the field of genetic medicine.

19. Affinia Therapeutics

• Website: affiniatx.com
• Ownership type: Private Equity
• Headquarters: Waltham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $110.0M, May 2021
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: touchdown-therapeutics

Affinia Therapeutics, based in Waltham, Massachusetts, is a biotechnology company that specializes in the development of innovative gene therapies. Founded in 2019, the company leverages its proprietary ART (Affinia Rationally-designed Therapies) platform to create targeted treatments for genetic diseases, with a particular focus on conditions affecting the heart and nervous system. Affinia's team comprises experienced professionals with a history of translating scientific research into viable therapies. The company has received significant funding, including a Series B round of $110 million in May 2021, which underscores its potential to make a meaningful impact in the gene therapy space. Affinia is dedicated to addressing the limitations of current gene therapy delivery methods, aiming to improve patient outcomes through advanced therapeutic designs and manufacturing processes.

20. Rampart Bioscience

• Website: rampartbio.com
• Ownership type: Venture Capital
• Headquarters: Monrovia, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $85.0M, October 2023
• Founded year: 2019
• Headcount: 1-10
• LinkedIn: rampart-bioscience

Rampart Bioscience, founded in 2019 and based in Monrovia, California, is a biotechnology company dedicated to creating innovative DNA-based medicines for genetic diseases. The firm is committed to addressing significant unmet medical needs by developing safe and effective gene therapies. With a team of experienced professionals in biotechnology and gene therapy, Rampart is focused on reshaping treatment options for patients suffering from genetically driven diseases. The company recently secured $85 million in Series A funding, which will support the advancement of their proprietary HALO platform. This platform is designed to produce potent, durable, and redosable therapies, with their lead program targeting hypophosphatasia, a rare genetic disorder. Rampart's approach integrates various scientific disciplines, aiming to provide long-lasting solutions for patients and their families.

21. Life Edit Therapeutics

• Website: lifeeditinc.com
• Ownership type: Private
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2017
• Headcount: 51-200
• LinkedIn: lifeedit

Life Edit Therapeutics, founded in 2017 and based in Durham, North Carolina, is a biotechnology firm focused on gene editing technologies. The company develops advanced solutions for genetic disorders, offering a range of products that include RNA-guided nucleases and therapeutic delivery systems. Life Edit is part of the ElevateBio ecosystem, which enhances its capabilities in creating transformative cell and gene therapies. Their technology platform is designed to facilitate both ex vivo and in vivo gene editing, allowing for targeted interventions in genetic diseases. Notably, Life Edit is working on a gene editing therapy for Huntington's disease, showcasing their commitment to addressing challenging genetic conditions. The company actively seeks partnerships with biotech and pharmaceutical firms to accelerate the development of innovative therapies, thereby contributing to the broader biopharmaceutical industry.

22. Belief BioMed

• Website: beliefbiomed.com
• Ownership type: Private
• Headquarters: Shanghai, Shanghai, China
• Employee distribution: China 100%
• Founded year: 2018
• Headcount: 201-500
• LinkedIn: belief-biomed

Belief BioMed Inc. is a Shanghai-based biotechnology firm founded in 2018, dedicated to the research, development, manufacturing, and clinical application of gene therapy products. The company focuses on creating innovative treatments for severe genetic and chronic diseases, utilizing advanced adeno-associated virus (AAV) vectors. Their product pipeline addresses significant unmet medical needs, including therapies for hemophilia, Parkinson's disease, and neuromuscular disorders. Notably, Belief BioMed's BBM-H901 has gained recognition as the first gene therapy for hemophilia in China, receiving approval for clinical trials from the National Medical Products Administration (NMPA). The company has also established a robust manufacturing platform in China, enhancing its capacity to produce clinical-grade gene therapies. With a commitment to making cutting-edge therapies accessible, Belief BioMed is actively contributing to advancements in the gene therapy field.

23. Miltenyi Biomedicine

• Website: miltenyibiomedicine.com
• Ownership type: Private
• Headquarters: Bergisch Gladbach, North Rhine-Westphalia, Germany
• Employee distribution: Germany 81%, United States (USA) 13%, Other 6%
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: miltenyi-biomedicine

Miltenyi Biomedicine, founded in 2019 and based in Bergisch Gladbach, Germany, is a biopharmaceutical company dedicated to the development of innovative cell and gene therapies. The company aims to provide personalized treatments for serious diseases, with a strong emphasis on cancer and regenerative therapies. Miltenyi Biomedicine is particularly focused on difficult-to-treat hematological cancers, utilizing CAR T technology to create effective immunotherapy options. Their research and development efforts are geared towards improving patient outcomes and expanding treatment options for conditions such as diffuse large B cell lymphoma and other aggressive cancers. The company operates under stringent regulatory standards, ensuring that their manufacturing processes comply with Good Manufacturing Practices (GMP). With a commitment to evidence-based medicine and patient-centered care, Miltenyi Biomedicine is positioned to make significant contributions to the field of gene therapy.

In Vivo Gene Therapy Insights: Key Companies

Want to Find More In Vivo Gene Therapy Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!